Cetuximab for the treatment of patients with colorectal cancer

被引：1
作者：
Cassidy, J. [1 ,2 ]
机构：
[1] Univ Glasgow, Ctr Oncol & Appl Pharmacol, Glasgow, Lanark, Scotland
[2] Univ Glasgow, Div Canc Sci & Mol Pathol, Glasgow, Lanark, Scotland
来源：
NATURE CLINICAL PRACTICE ONCOLOGY | 2008年 / 5卷 / 06期
关键词：
antibody; cancer; cetuximab; colorectal; EGFR;
D O I：
10.1038/ncponc1130
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：310 / 311
页数：2
相关论文
共 3 条
[1]   Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].
Cunningham, D ;
Humblet, Y ;
Siena, S ;
Khayat, D ;
Bleiberg, H ;
Santoro, A ;
Bets, D ;
Mueser, M ;
Harstrick, A ;
Verslype, C ;
Chau, I ;
Van Cutsem, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345
[2]   KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab [J].
Lievre, Astrid ;
Bachet, Jean-Baptiste ;
Boige, Valerie ;
Cayre, Anne ;
Le Corre, Delphine ;
Buc, Emmanuel ;
Ychou, Marc ;
Bouche, Olivier ;
Landi, Bruno ;
Louvet, Christophe ;
Andre, Thierry ;
Bibeau, Frederic ;
Diebold, Marie-Daniele ;
Rougier, Philippe ;
Ducreux, Michel ;
Tomasic, Gorana ;
Emile, Jean-Francois ;
Penault-Llorca, Frederique ;
Laurent-Puig, Pierre .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (03) :374-379
[3]   A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity [J].
Tol, J. ;
Koopman, M. ;
Rodenburg, C. J. ;
Cats, A. ;
Creemers, G. J. ;
Schrama, J. G. ;
Erdkamp, F. L. G. ;
Vos, A. H. ;
Mol, L. ;
Antonini, N. F. ;
Punt, C. J. A. .
ANNALS OF ONCOLOGY, 2008, 19 (04) :734-738
1